Vanguard Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Vanguard Asset Management's VRTX Position: Q3 2026 in Review
Vanguard Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q3 2026, buying an estimated $20M and bringing the position to 533,246 shares worth $279M. The position accounts for 0.17% of the portfolio, ranked #95.
Vanguard Asset Management first reported a position in VRTX in Q1 2026 and has held it in 3 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Vanguard Asset Management held 533,246 shares of Vertex Pharmaceuticals worth $279M as of Q3 2026.
- Vanguard Asset Management bought 39,060 Vertex Pharmaceuticals shares in Q3 2026, an estimated $20M.
- Vertex Pharmaceuticals made up 0.17% of Vanguard Asset Management's portfolio in Q3 2026, its #95 holding.
- Vanguard Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.